The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil

PharmacoEconomics

Volumn 36, Issue 2, 2018, Pages 161-173

  Lemos, Livia Lovato Pires de ^a   Guerra Júnior, Augusto Afonso ^a   Santos, Marisa ^b   Magliano, Carlos ^b   Diniz, Isabela ^a   Souza, Kathiaja ^c,d   Pereira, Ramon Gonçalves ^a   Alvares, Juliana ^a   Godman, Brian ^e,f,g   Bennie, Marion ^f   Zimmermann, Ivan Ricardo ^c   dos Santos, Vânia Crisitna Canuto ^c   Pretramale, Clarice Alegre ^c   Acurcio, Francisco de Assis ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO NACIONAL DE CARDIOLOGIA   (Brazil)

^c MINISTÉRIO DA SAÚDE   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOLOGICAL ADJUVANT;

BRAZIL; COCHRANE LIBRARY; CONSULTATION; DECISION MAKING; HUMAN; INVESTMENT; META ANALYSIS (TOPIC); METHODOLOGY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); COMPARATIVE STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; PRACTICE GUIDELINE; PUBLIC HEALTH; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; BRAZIL; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON BETA-1A; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES AS TOPIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85033707953     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-017-0579-0     Document Type: Review

References (62)

1. Atos do Poder Legislativo, República Federativa do Brasil. Lei No 12.401, de 28 de abril de 2011. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2011. p. 1–2.
2. Maloney MA, Schwartz L, O’Reilly D, Levine M. Drug disinvestment frameworks: components, challenges, and solutions. Int J Technol Assess Health Care. 2017;33(2):261–9.
3. Orso M, de Waure C, Abraha I, Nicastro C, Cozzolino F, Eusebi P, et al. Health technology disinvestment worldwide: overview of programs and possible determinants. Int J Technol Assess Health Care. 2017;33(2):239–50.
4. Brett J, Elshaug AG, Bhatia RS, Chalmers K, Badgery-Parker T, Pearson S-A. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implement Sci. 2017;12(1):58.
5. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33:905–24.
6. o 7.646, de 21 de dezembro de 2011. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2011. p. 3–5.
7. Guerra-Júnior AA, Lemos L, Godman B, Bennie M, Osorio de Castro C, Alvares J, et al. Health technology performance assessment: real-world evidence for public healthcare sustainability. Int J Technol Assess Health Care. 2017;33(2):279-28.
8. da Gama Pereira ABCN, Lacativa MCS, da Costa Pereira FFC, Alvarenga RMP. Prevalence of multiple sclerosis in Brazil: a systematic review. Mult Scler Relat Disord. 2015;4:572–9.
9. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.
10. Hauser SL, Goodwin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. 17th ed. New York: McGraw-Hill Medical; 2008. p. 2611–21.
11. Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis—a quiet revolution. Nat Rev Neurol. 2015;11:246–246.
12. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116:117–34.
13. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.
14. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133–46.
15. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.
16. Goldenberg MM. Multiple sclerosis review. P T. 2012;37:175–84.
17. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60.
18. Ingwersen J, Aktas O, Hartung H-P. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016;13:47–57.
19. Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Health Drug Benefits. 2015;8:448–53.
20. Secretaria de Atenção à Saúde, Ministério da Saúde, República Federativa do Brasil. Portaria n° 97, de 22 de março de 2001. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2001. p. 114.
21. o 391, de 5 de maio de 2015. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2015. p. 40.
22. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D’Amico R, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545–52.
23. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903–14.
24. O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889–97.
25. Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9:CD011381. https://doi.org/10.1002/14651858.CD011381.pub2.
26. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ Br Med J Publ Group. 2011;343:d5928.
27. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429–37.
28. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–655.
29. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285–94.
30. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498–504.
31. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing–remitting multiple sclerosis: results after 18 months of therapy. Mult Scler. 2001;7:349–53.
32. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–60.
33. Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66:1056–60.
34. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006;113:283–7.
35. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29:2031–48.
36. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327–40.
37. de Caires Souza AL, de Souza ALC, de Assis Acurcio F, Júnior AAG, do Nascimento RCRM, Godman B, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12:19–32.
38. o 27, de 6 de julho de 2016. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2016. p. 35.
39. Drugs@FDA: FDA approved drug products. http://www.fda.gov/drugsatfda. Accessed 16 May 2017.
40. Consulta a produtos registrados - Anvisa [Internet]. http://portal.anvisa.gov.br/consulta-produtos-registrados. Accessed 16 May 2017.
41. Henshall C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of technologies in current practice: the challenge of “disinvestment”. Int J Technol Assess Health Care. 2012;28:203–10.
42. CADTH. Canadian Agency for Drugs and Technologies in Health. Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis. https://www.cadth.ca/sites/default/files/pdf/TR0004_RRMS_ScienceReport_e.pdf. Accessed 23 May 2017.
43. NICE. Technology appraisal guidance 32. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. 2002. https://www.nice.org.uk/Guidance/TA32. Accessed 24 May 2017.
44. Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677.
45. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.
46. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14(5):497–505.
47. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657–65.
48. Top multiple sclerosis drugs worldwide by revenue 2013 | Statistic [Internet]. Statista. [cited 2017 May 5]. https://www.statista.com/statistics/372273/leading-ten-ms-medications-by-revenue/. Accessed 31 May 2017.
49. Aitken M, Kleinrock M, Pennente K, Lyle J, Nass D, Caskey L. Medicines use and spending in the U.S. A review of 2015 and outlook to 2020 [Internet]. IMS Institute for Healthcare Informatics; 2016. http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/medicines-use-and-spending-in-the-us-a-review-of-2015-and-outlook-to-2020. Accessed 31 May 2017.
50. o 19, de 19 de abril de 2017. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2017. p. 58.
51. o 14, de 13 de março de 2017. Diário Oficial da União. Brasília, DF: Imprensa Nacional; 2017. p. 53.
52. FIOCRUZ. Technology transfer beta interferons. https://agencia.fiocruz.br/assinado-acordo-para-transfer%C3%AAncia-de-tecnologia-do-betainterferona-1a. Accessed 5 Apr 2017.
53. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics. 2009;27(5):435–8.
54. Hesse U, Godman B, Petzold M, Martin A, Malmstrom RE. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl Health Econ Health Policy. 2013;11(6):677–85.
55. Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J Comp Effect Res. 2014;3(1):41–51.
56. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476–81.
57. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–62.
58. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90:996–1000.
59. Ghinea N, Kerridge I, Lipworth W. If we don’t talk about value, cancer drugs will become terminal for health systems [Internet]. The Conversation. 2015. http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072. Accessed 15 May 2017.
60. Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8:77–94.
61. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Methodological Guidelines: Health Technology Performance Assessment. Brasília, DF: Ministério da Saúde do Brasil
62. Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, et al. Dabigatran—a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:1–31.